Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population

Journal of Infectious Diseases

Volumn 197, Issue 12, 2008, Pages 1662-1668

  Date, Anand A ^a,e,i   Kyaw, Moe H ^a,g   Rue, Alison M ^a   Klahn, Julie ^b   Obrecht, Leann ^b   Krohn, Terry ^c   Rowland, Josh ^d   Rubin, Steve ^f   Safranek, Thomas J ^e   Bellini, William J ^a   Dayan, Gustavo H ^a,h  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b UNIVERSITY OF NEBRASKA AT KEARNEY   (United States)

^c Two Rivers Public Health Department   (United States)

^d Nebraska Public Health Laboratory   (United States)

^e Nebraska Health and Human Services System   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h Sanofi Pasteur MSD

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY;

ADULT; AGE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG MECHANISM; ENZYME IMMUNOASSAY; FEMALE; GENDER; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNIVERSITY STUDENT; VACCINATION;

ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VIRUS; NEBRASKA; TIME FACTORS;

EID: 46349104472     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/588197     Document Type: Article

References (40)

1. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999; 77:3-14.
2. Centers for Disease Control and Prevention. Recommendation of the Public Health Service Advisory Committee on Immunization Practices: mumps vaccine. MMWR Morb Mortal Wkly Rep 1977; 26:393-4.
3. Centers for Disease Control and Prevention. Measles prevention: recommendations of the Immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1989; 38 (Suppl 9):1-18.
4. Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2003. MMWR 2005; 52:1-85.
5. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:585-9.
6. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:658-61.
7. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:988-93.
8. Centers for Disease Control and Prevention. Update: multistate outbreak of mumps - United States, Jan 1-May 2, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:559-63.
9. Centers for Disease Control and Prevention. Update: mumps activity - United States, Jan 1-Oct 7. MMWR Morb Mortal Wkly Rep 2006; 55:1152-3.
10. Narita M, Matsuzono Y, Takekoshi Y, et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol 1998; 5:799-803.
11. Mauldin J, Carbone K, Hsu H, Yolken R, Rubin S. Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays. J Clin Microbiol 2005; 43:4847-51.
12. Hummel KB, Erdman DD, Heath J, Bellini W. Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol 1992; 30:2874-80.
13. SAS Institute. Getting started guide for SAS® 9.1.3. Cary, NC: SAS Institute, 2006.
14. Wharton M, Cochi SL, Hutcheson RH, Bistowish JM, Schaffner W. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988; 158:1253-60.
15. Cheek JE, Baron R, Atlas H, Wilson DL, Crider RD Jr. Mumps outbreak in a highly vaccinated school population: evidence for large-scale vaccination failure. Arch Pediatr Adolesc Med 1995; 149:774-8.
16. Sullivan KM, Halpin TJ, Marks JS, Kim-Farley R. Effectiveness of mumps vaccine in a school outbreak. Am J Dis Child 1985; 139:909-12.
17. Centers for Disease Control and Prevention. Efficacy of mumps vaccine - Ohio. MMWR Morb Mortal Wkly Rep 1983; 32:391-2.
18. Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994; 169:77-82.
19. Hersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991; 119:187-93.
20. Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 2004; 22:2713-6.
21. Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccine. Vaccine 1995; 13:799-802.
22. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two dose MMR vaccination. Vaccine 1995; 13:1617-22.
23. Plotkin S, Orenstein W. Vaccines. 4th ed. Philadelphia, PA: Saunders, 2004:441-469 (chapter 20).
24. Harling R, White JM, Ramsay ME, Macsween KF, van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005; 23:4070-4.
25. Sartorius B, Penttinen P, Nilsson J, et al. An outbreak of mumps in Sweden, February-April 2004. Euro Surveill 2005; 10:191-9.
26. Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007; 13:12-7.
27. Schaffzin JK, Pollock L, Schulte C, et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics 2007; 120:e862-8.
28. Sartorius B, Penttinen P, Nilsson J, et al. An outbreak of mumps in Sweden, February-April 2004. Euro Surveill 2005; 10:191-9.
29. Gut JP, Lablanche C, Behr S, Kim A. Symptomatic mumps virus reinfections. J Med Virol 1995; 45:17-23.
30. Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics 2005; 116:1287-91.
31. Parker AA, Staggs W, Dayan GH, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006; 355:447-55.
32. Simpson RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952; 2:549-54.
33. Anderson RM, May RM. Infectious disease of humans: dynamics and control. New York: Oxford University Press; 1992:70.
34. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
35. Ennis FA. Immunity to mumps in an institutional epidemic: correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies. J Infect Dis 1969; 119:654-7.
36. López Hernández B, Martín Vélez RM, Román García C, Peñalver Sánchez I, López Rosique JA. An epidemic outbreak of mumps: a study of vaccine efficacy. Aten Primaria 2000; 25:148-52.
37. Sanz JC, Mosquera MM, Echevarría JE, et al. Sensitivity and specificity of immunoglobulin G titer for the diagnosis of mumps virus in infected patients depending on vaccination status. APMIS 2006; 114:788-94.
38. Bloom S, Wharton M. Mumps outbreak among young adults in UK. BMJ 2005; 331:E363-4.
39. Rubin S, Li Q, Audet S, et al. Mumps virus strain-specific antibody neutralization and waning immunity following vaccination [abstract 851]. In: Scientific program and abstracts of the 26th Annual Meeting of the American Society for Virology (Corvallis, Oregon). 2007.
40. Vyse AJ, Gay NJ, Hesketh LM, et al. Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiol Infect 2006; 134:1303-12.